Related Experiment Video
Updated: Nov 5, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Subgrouping by gene expression profiles to improve relapse risk prediction in paediatric B-precursor acute
Qingsheng Huang1,2, Jiayong Zhong2,3, Huan Gao2
1School of Mathematics and Statistics, Hanshan Normal University, Chaozhou, China.
Insights
Subgrouping B-precursor acute lymphoblastic leukemia (ALL) patients by gene expression improves prediction of minimal residual disease (MRD) and relapse-free survival (RFS). This approach helps manage ALL heterogeneity for better treatment tailoring.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Relapsed acute lymphoblastic leukemia (ALL) is a major cause of childhood cancer mortality.
- Current treatment stratification faces challenges due to ALL heterogeneity and subtyping difficulties.
Purpose of the Study:
- To subgroup B-precursor ALL patients using gene expression profiles.
- To develop predictive models for minimal residual disease (MRD) and relapse-free survival (RFS) within these subgroups.
Main Methods:
- Unsupervised subgrouping using non-negative matrix factorization and minimum description length.
- Logistic and Cox regression with elastic net regularization for predictive modeling.
- Validation of MRD and RFS prediction models across subgroups.
Main Results:
- Subgrouping improved MRD prediction accuracy in one subgroup (TCF3-PBX1 subtype), achieving AUC of 0.986 (training) and 1.0 (test).
- RFS prediction models showed acceptable concordance and identified high-risk patients in three subgroups.
- Identified subgroup-specific genes crucial for prediction models.
Conclusions:
- Gene expression-based subgrouping effectively addresses B-precursor ALL heterogeneity.
- Improved prediction of MRD and RFS can be achieved through tailored subgroup analysis.
- This strategy enhances personalized treatment approaches for pediatric ALL.
Abstract:
Relapsed acute lymphoblastic leukaemia (ALL) remains a prevalent paediatric cancer and one of the most common causes of mortality from malignancy in children. Tailoring the intensity of therapy according to early stratification is a promising strategy but remains a major challenge due to heterogeneity and subtyping difficulty. In this study, we subgroup B-precursor ALL patients by gene expression profiles, using non-negative matrix factorization and minimum description length which unsupervisedly determines the number of subgroups. Within each of the four subgroups, logistic and Cox regression with elastic net regularization are used to build models predicting minimal residual disease (MRD) and relapse-free survival (RFS) respectively. Measured by area under the receiver operating characteristic curve (AUC), subgrouping improves prediction of MRD in one subgroup which mostly overlaps with subtype TCF3-PBX1 (AUC = 0·986 in the training set and 1·0 in the test set), compared to a global model published previously. The models predicting RFS displayed acceptable concordance in training set and discriminate high-relapse-risk patients in three subgroups of the test set (Wilcoxon test p = 0·048, 0·036, and 0·016). Genes playing roles in the models are specific to different subgroups. The improvement of subgrouped MRD prediction and the differences of genes in prediction models of subgroups suggest that the heterogeneity of B-precursor ALL can be handled by subgrouping according to gene expression profiles to improve the prediction accuracy.
More Related Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018